This article is based on a poster originally authored by Anne J Hout, Nikki Claassen, Ilse H Wolters, Johanna FB Pagano, and Karthikeyan Devaraju. Stable expression in gene therapies with transposons, ...

Nabsys 2.0, LLC ("Nabsys"), a pioneer in Electronic Genome Mapping (EGM), today announced the publication of a new preprint demonstrating that CRISPR/Cas9 can be used to customize how EGM identifies ...

CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310 ®, its ...

CRISPR-Cas9 removed an extra chromosome 21 from some Down syndrome cells in the lab. Learn what the 30.6% result means and ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the double ...

This article and associated images are based on a poster originally authored by Dhruv Sunil Choudhary and presented at ELRIG Drug Discovery 2025 in affiliation with the University of Westminster. This ...

Development of bespoke therapies has been a driving goal in medical research. This year, the announcement of the first patient treated with personalized CRISPR therapy, Baby KJ, highlights this ...

Gene-editing techniques could soon allow researchers to replace entire genes and engineer complex cellular circuits — if the ...

In December 2020, the New England Journal of Medicine published a paper titled CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia, marking an exciting new chapter in the treatment of ...

Japanese researchers used CRISPR-Cas9 to remove the extra chromosome 21 from cells in a lab. It’s a real breakthrough — but ...